6 completed, 5 active not recruiting, 1 not yet recruiting, 1 recruiting. 9 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Active not recruiting 3, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Beijing QL Biopharmaceutical Co.,Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) zovaglutide Arm 1, zovaglutide Arm 2, semaglutide - Obesity | Phase 2 | Not yet recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 210 | 2026-10-12 | 2026-09-10 |
| A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults ZT002 injection, ZT002 injection matching placebo - Overweight, Obesity | Phase 1 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 40 | 2026-07-15 | 2026-10-21 |
| Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants ZT002 injection, metformin, warfarin, ZT002 injection, rosuvastatin, digoxin - Overweight,Obesity | Phase 1 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 60 | 2026-05-27 | 2026-10-21 |
| A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants Zovaglutide - Overweight , Obesity | Phase 1 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 40 | 2026-04-13 | 2026-10-21 |
| A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) Zovaglutide dose 1, Zovaglutide dose 2, Placebo - Overweight , Obesity | Phase 3 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 755 | 2026-01-16 | 2026-08-03 |
| Efficacy and Safety of ZT006 in Overweight and Obese Participants ZT006, Placebo of ZT006 - Overweight , Obesity | Phase 2 | Active not recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 184 | 2025-12-12 | 2026-06-12 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers ZT003 - Part1 (Single ascending dose ), ZT003 - Part 2(Multiple ascending dose ) - Healthy | Phase 1 | Recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 72 | 2025-10-16 | 2026-07-27 |
| Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants ZT006, Placebo of ZT006 - Overweight,Obesity | Phase 1 | Completed | Beijing QL Biopharmaceutical Co.,Ltd | 94 | 2024-11-28 | 2025-12-29 |
| A Study of ZT002 Injection With Subjects With Overweight or Obesity ZT002 Injection, ZT002 Placebo - Overweight or Obesity | Phase 2 | Completed | Beijing QL Biopharmaceutical Co.,Ltd | 303 | 2024-08-14 | 2025-12-10 |
| A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM) ZT002 Injection, ZT002 Placebo - Type 2 Diabetes | Phase 1 / Phase 2 | Completed | Beijing QL Biopharmaceutical Co.,Ltd | 27 | 2024-02-19 | 2025-07-15 |
| A Study of ZT002 Injection in Participants With Overweight or Obesity ZT002 Injection, Placebo - Overweight or Obesity | Phase 1 | Completed | Beijing QL Biopharmaceutical Co.,Ltd | 28 | 2023-11-21 | 2026-01-16 |
| A SAD Study of ZT002 Injection in Healthy Participants ZT002, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Completed | Beijing QL Biopharmaceutical Co.,Ltd | 28 | 2023-06-19 | 2024-05-21 |
| A Study of ZT002 in Healthy Participants ZT002, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Completed | QL Biopharmaceutical Australia Pty Ltd | 32 | 2022-09-02 | 2026-01-16 |
Obesity (9) · Overweight (8) · Diabetes Mellitus, Type 2 (3)
Digoxin (1) · Metformin (1) · Rosuvastatin Calcium (1) · Warfarin (1) · semaglutide (1)
China (11) · Australia (2)
Linong Ji, MD (3) · Aixin Shi, Master (1) · Chengqian Li, MD (1) · Huan Zhou, PhD (1) · Kristi McLendon (1) · Linong Ji, Doctor (1) · Qin Yu, Master (1) · Quankun Zhuang, Doctor (1) · Wei Hu, MD (1) · Wei Zhao, PhD (1) · Xiaoli Li, Master (1) · Xuemei Liu, Doctor (1) · Yijun Du, Master (1) · Yu Cao, PhD (1)